FDA approves three new Takeda type 2 diabetes therapies
Takeda expects to launch the type 2 diabetes therapies as adjuncts to diet and exercise in the summer of 2013. Takeda Pharmaceuticals USA president Douglas Cole said, "Takeda
Ultragenyx Pharmaceutical has received accelerated approval from the US Food and Drug Administration (FDA) for its gene therapy, Genglycos (pariglasgene brecaparvovec-opnr), to treat glycogen storage disease type Ia (GSDIa).
The single dose Pneumococcal 13-valent conjugate vaccine [Diphtheria CRM197 Protein] will provide protection from invasive disease caused by 13 Streptococcus pneumoniae serotypes. Pfizer vaccine president Susan Silbermann said,
The CE-marked solution enables clinicians to plan and perform high-dose-rate (HDR) brachytherapy treatments for prostate cancer using real-time ultrasound guidance. The treatment involves delivery of radiotherapy from inside
The commencement of the study trigered a $30m milestone payment to Threshold Pharmaceuticals from Merck under a license and co-development agreement signed between the companies. Randomized, placebo-controlled Phase
In the double-blind study, 845 patients were administered with Folfox or Folfiri and bevacizumab as the front-line treatment of locally-advanced or metastatic colorectal cancer. Neulasta demonstrated the significant